Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 11, 2014

IROA and the University of Florida Take On Liver-Disease Biomarkers

  • IROA Technologies and the University of Florida (UF) agreed to collaborate on the analysis and validation of clinical tissue for finding potential biomarkers of liver cancer and other liver diseases. The collaboration will leverage IROA’s patented technology, software, and expertise along with the UF’s Clinical and Translational Science Institute Biorepository, which contains a diverse collection of normal and diseased human tissues and may be used for IRB-approved research.

    In addition, UF’s Southeast Center for Integrated Metabolomics (SECIM) will provide metabolic profiling using the IROA protocol as a foundation for exploring liver biochemical diversity and disease response. UF will also provide medical support and interpretation of results through an established expert liver disease and mass spectrometry advisory committee.

    IROA initially partnered with UF in September 2013 to join in the establishment of the SECIM, which was awarded a five-year $9 million grant from the NIH. The SECIM is developing an integrated metabolomics service to provide high-quality data, user-friendly statistical analysis tools, training, and pilot funding to help users get the most out of a metabolomics study, according to officials at the center.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »